Trust Co. of Toledo NA OH raised its holdings in GSK plc (NYSE:GSK – Free Report) by 6.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,679 shares of the pharmaceutical company’s stock after acquiring an additional 2,015 shares during the period. Trust Co. of Toledo NA OH’s holdings in GSK were worth $1,336,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Register Financial Advisors LLC bought a new stake in GSK during the first quarter valued at approximately $31,000. Ashton Thomas Private Wealth LLC purchased a new stake in GSK during the second quarter valued at about $37,000. Richardson Financial Services Inc. bought a new stake in GSK during the fourth quarter worth about $40,000. PrairieView Partners LLC purchased a new stake in GSK in the second quarter worth approximately $47,000. Finally, Triad Wealth Partners LLC purchased a new position in shares of GSK during the second quarter worth approximately $49,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.
Insider Buying and Selling at GSK
In other news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.00% of the company’s stock.
Wall Street Analyst Weigh In
GSK Trading Down 2.7 %
NYSE GSK opened at $38.37 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The stock has a market cap of $79.52 billion, a P/E ratio of 13.90, a price-to-earnings-growth ratio of 1.31 and a beta of 0.66. The stock has a 50 day simple moving average of $41.59 and a two-hundred day simple moving average of $41.53.
GSK (NYSE:GSK – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The business had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. On average, analysts forecast that GSK plc will post 4.17 earnings per share for the current year.
GSK Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be paid a $0.3843 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a yield of 4.01%. The ex-dividend date is Friday, August 16th. GSK’s dividend payout ratio is presently 54.71%.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
- Five stocks we like better than GSK
- Conference Calls and Individual Investors
- When Is the Best Time to Invest in Mutual Funds?
- How to Invest in the Best Canadian StocksĀ
- Is NVIDIA Stock in a Correction or Consolidation?
- How to Invest in Small Cap StocksĀ
- 3 Oversold Stocks with Big RSI Rebound Potential
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.